IF: 0.644
REUTERS THOMSON

Development of Single Chain Antibodies to P185 Tumor Antigen

AUTHORS

F Nejatollahi 1 , * , Z Malek-Hosseini 2 , D Mehrabani 2

AUTHORS INFORMATION

1 Assistant Professor of Department of Immunology, Shiraz University of Medical Sciences, nejatollaf@sums.ac.ir, Fars, Iran

2 Department of Immunology, School of Medicine, Shiraz University of Medical Sci-ences, Fars, Iran

ARTICLE INFORMATION

Iranian Red Crescent Medical Journal: 10 (4); 298-302
Article Type: Research Article
Received: July 20, 2008
Accepted: September 7, 2008

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: The human heavy (VH) and light (VL) chain variable genes are amplified and randomly assembled together and cloned into the minor coat protein gene (g3p) of M13 bacteriophage. The resulting library of scFv is expressed on the phage as g3p fusion protein. The high affinity specific scFv antibodies can be selected against a key antigen using panning process. Our aim was development of scFv antibodies against P185 tumor antigen by recombinant phage antibody system and panning process.

 

Methods: Antibody engineering technology was applied to lymphocyte mRNA of a non-immune donor and a scFv library was constructed. The library was panned against an immunodominant epitope of P185 which its reactivity had been tested with sera from breast cancer patients. DNA fingerprinting of the scFvs selected the predominated clones. These were then screened by ELISA.

 

Results: A large library including high repertoires of VH and VL was constructed. DNA fingerprinting differentiated a number of clones. After selection against the immunodominant epitope of P185, nine clones were differentiated including two predominated scFv antibodies. The predominated antibodies were bound to the corresponding epitope and produced a positive ELISA.

 

Conclusion: The high affinity P185 specific scFv antibodies which were originated from human genes and bound specifically to the P185 epitope are valuable clinical agents and have the potential to be used in cancer immunotherapy in which P185 overexpression and metastasis occurs.

Keywords

scFv Human recombinant antibody P185 Cancer immunotherapy

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: